ISSUE 1384
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Zolpidem oral spray (Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate (Ambien, and others), has been approved by the FDA for short-term treatment of insomnia characterized by difficulty falling asleep.
ZOLPIDEM — Zolpidem is the most frequently prescribed hypnotic in the US. Rapid-acting with a short half-life, it is available as an immediate-release (IR) tablet, a sublingual tablet (Edluar)1 and an extended-release (ER) tablet (Ambien CR). A new sublingual tablet recently approved for middle-of-the-night awakening (Intermezzo) will be reviewed in a future issue of The Medical Letter.
RELATED DRUGS — Zolpidem, zaleplon (Sonata, and others), and eszopiclone (Lunesta) are benzodiazepine receptor agonists; they are not benzodiazepines, but appear to bind
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1384b
Electronic, downloadable article - $45